Compare Albemarle Corp. (ALB) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Crispr Therapeutics AG — how do they compare? Albemarle Corp. trades at $128.07 (market cap $15.22B), while Crispr Therapeutics AG trades at $58.9 (market cap $5.98B). The key difference: Albemarle Corp. is far larger — about 2.5× Crispr Therapeutics AG's market cap, and Albemarle Corp. pays a 1.26% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ALB | CRSP | |
|---|---|---|
Market Cap | $15.22B | $5.98B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $76.78 |
52-Week Low | $67.30 | $44.34 |
Enterprise Value | $18.24B | $4.33B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
CRISPR Therapeutics (CRSP) trades at $60.77, up 1.15% with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company maintains strong cash reserves despite negative profitability metrics, with recent FDA approval for Casgevy pediatric use expanding its commercial potential. Technical indicators show the stock trading near pivot point resistance at $61 with RSI levels suggesting potential overbought conditions.
While CRSP shows promising growth potential with its pioneering gene-editing technology and recent regulatory wins, investors face significant risks from persistent negative margins and cash burn. The stock offers 19.6% upside to the consensus price target of $72.67, but requires careful monitoring of commercialization progress and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
